Sol Beccari, Esraa Mohamed, Viva Voong, Stephanie Hilz, Marisa Lafontaine, Anny Shai, Yunita Lim, Jerry Martinez, Benjamin Switzman, Ryon L Yu, Janine M Lupo, Eddie F Chang, Shawn L Hervey-Jumper, Mitchel S Berger, Joseph F Costello, Joanna J Phillips
Biomarker-driven therapeutic clinical trials require implementation of standardized, evidence-based practices for sample collection. In diffuse glioma, phosphatidylinositol 3 (PI3)-kinase/AKT/mTOR (PI3/AKT/mTOR) signaling is an attractive therapeutic target for which window of opportunity clinical trials could facilitate identification of promising new agents. Yet, the relevant preanalytic variables and optimal tumor sampling methods necessary to measure pathway activity are unknown. To address this, we used a murine model for IDH-wildtype glioblastoma (GBM) and human tumor tissue, including IDH-wildtype GBM and IDH-mutant diffuse glioma...
April 6, 2024: Modern Pathology